Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.8 USD | +2.13% | -7.16% | +69.01% |
06-25 | Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp??) Program | CI |
06-24 | Humacyte, Inc.(NasdaqGS:HUMA) added to S&P Biotechnology Select Industry Index | CI |
Evolution of the average Target Price on Humacyte, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Humacyte, Inc.
Piper Sandler | |
HC Wainwright | |
Cantor Fitzgerald | |
BTIG | |
Cowen | |
Oppenheimer |
EPS Revisions
- Stock Market
- Equities
- HUMA Stock
- Consensus Humacyte, Inc.